Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of MK-3655 in Pre-cirrhotic NASH
jRCT2051200083Phase 2Completed
- Sponsor
- MSD
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of NGM313 in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by MSD. Primary endpoints: Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks, Percentage of Participants Who Experienced an Adverse Event (AE) and 1 more. Started Jan 2021; status: completed.
02
Drugs
NGM313
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2051200083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200083.